0 13 Dysregulation dysregulation NN 14 16 of of IN 17 26 monocytic monocytic JJ 27 34 nuclear nuclear JJ 35 47 factor-kappa factor-kappa NN 48 49 B b NN 50 52 by by IN 53 61 oxidized oxidize VBN 62 73 low-density low-density JJ 74 85 lipoprotein lipoprotein NN 85 86 . . . 88 95 Nuclear nuclear JJ 96 108 factor-kappa factor-kappa NN 109 110 B B NNP 111 112 ( ( ( 112 120 NF-kappa NF-kappa NNP 121 127 B)/Rel B)/Rel NNP 128 141 transcription transcription NN 142 149 factors factor NNS 150 153 may may MD 154 156 be be VB 157 165 involved involve VBN 166 168 in in IN 169 184 atherosclerosis atherosclerosis NN 184 185 , , , 186 188 as as IN 189 191 is be VBZ 192 201 suggested suggest VBN 202 204 by by IN 205 208 the the DT 209 217 presence presence NN 218 220 of of IN 221 230 activated activate VBN 231 239 NF-kappa NF-kappa NNP 240 241 B B NNP 242 244 in in IN 245 250 human human JJ 251 266 atherosclerotic atherosclerotic JJ 267 274 lesions lesion NNS 274 275 . . . 276 279 The the DT 280 283 aim aim NN 284 286 of of IN 287 290 the the DT 291 298 present present JJ 299 304 study study NN 305 308 was be VBD 309 311 to to TO 312 323 investigate investigate VB 324 327 the the DT 328 335 effects effect NNS 336 338 of of IN 339 347 oxidized oxidize VBN 348 351 LDL LDL NNP 352 353 ( ( ( 353 358 oxLDL oxldl NN 358 359 ) ) ) 360 362 on on IN 363 366 the the DT 367 375 NF-kappa NF-kappa NNP 376 377 B B NNP 378 384 system system NN 385 387 in in IN 388 393 human human JJ 394 399 THP-1 thp-1 NN 400 409 monocytic monocytic JJ 410 415 cells cell NNS 416 418 as as RB 419 423 well well RB 424 426 as as IN 427 435 adherent adherent JJ 436 445 monocytes monocyte NNS 445 446 . . . 447 450 Our our PRP$ 451 458 results result NNS 459 470 demonstrate demonstrate VBP 471 475 that that IN 476 486 short-term short-term JJ 487 497 incubation incubation NN 498 500 of of IN 501 506 these these DT 507 512 cells cell NNS 513 517 with with IN 518 523 oxLDL oxldl NN 524 533 activated activate VBD 534 541 p50/p65 p50/p65 NN 542 552 containing contain VBG 553 561 NF-kappa NF-kappa NNP 562 563 B B NNP 564 570 dimers dimer NNS 571 574 and and CC 575 582 induced induce VBD 583 586 the the DT 587 597 expression expression NN 598 600 of of IN 601 604 the the DT 605 611 target target NN 612 616 gene gene NN 617 621 IL-8 il-8 NN 621 622 . . . 623 627 This this DT 628 638 activation activation NN 639 641 of of IN 642 650 NF-kappa NF-kappa NNP 651 652 B B NNP 653 656 was be VBD 657 666 inhibited inhibit VBN 667 669 by by IN 670 673 the the DT 674 685 antioxidant antioxidant NN 686 689 and and CC 690 694 H2O2 h2o2 NN 695 704 scavenger scavenger NN 705 716 pyrrolidine pyrrolidine NN 717 732 dithiocarbamate dithiocarbamate NN 733 736 and and CC 737 740 the the DT 741 751 proteasome proteasome NN 752 761 inhibitor inhibitor NN 762 765 PSI PSI NNP 765 766 . . . 767 770 The the DT 771 784 oxLDL-induced oxldl-induced JJ 785 793 NF-kappa NF-kappa NNP 794 795 B B NNP 796 806 activation activation NN 807 810 was be VBD 811 822 accompanied accompany VBN 823 825 by by IN 826 828 an an DT 829 836 initial initial JJ 837 846 depletion depletion NN 847 849 of of IN 850 851 I i NN 852 857 kappa kappa NN 858 865 B-alpha B-alpha NNP 866 874 followed follow VBN 875 877 by by IN 878 879 a a DT 880 886 slight slight JJ 887 896 transient transient JJ 897 905 increase increase NN 906 908 in in IN 909 912 the the DT 913 918 level level NN 919 921 of of IN 922 926 this this DT 927 936 inhibitor inhibitor NN 937 944 protein protein NN 944 945 . . . 946 948 In in IN 949 957 contrast contrast NN 957 958 , , , 959 968 long-term long-term JJ 969 978 treatment treatment NN 979 983 with with IN 984 989 oxLDL oxldl NN 990 999 prevented prevent VBD 1000 1003 the the DT 1004 1030 lipopolysaccharide-induced lipopolysaccharide-induced JJ 1031 1040 depletion depletion NN 1041 1043 of of IN 1044 1045 I i NN 1046 1051 kappa kappa NN 1052 1059 B-alpha B-alpha NNP 1059 1060 , , , 1061 1072 accompanied accompany VBN 1073 1075 by by IN 1076 1078 an an DT 1079 1089 inhibition inhibition NN 1090 1092 of of IN 1093 1097 both both CC 1098 1106 NF-kappa NF-kappa NNP 1107 1108 B B NNP 1109 1119 activation activation NN 1120 1123 and and CC 1124 1127 the the DT 1128 1138 expression expression NN 1139 1141 of of IN 1142 1147 tumor tumor NN 1148 1156 necrosis necrosis NN 1157 1169 factor-alpha factor-alpha NN 1170 1173 and and CC 1174 1187 interleukin-1 interleukin-1 NN 1188 1192 beta beta NN 1193 1198 genes gene NNS 1198 1199 . . . 1200 1205 These these DT 1206 1218 observations observation NNS 1219 1226 provide provide VBP 1227 1237 additional additional JJ 1238 1246 evidence evidence NN 1247 1251 that that IN 1252 1257 oxLDL oxldl NN 1258 1260 is be VBZ 1261 1262 a a DT 1263 1269 potent potent JJ 1270 1279 modulator modulator NN 1280 1282 of of IN 1283 1287 gene gene NN 1288 1298 expression expression NN 1299 1302 and and CC 1303 1310 suggest suggest VBP 1311 1315 that that IN 1316 1317 ( ( ( 1317 1331 dys)regulation dys)regulation NN 1332 1334 of of IN 1335 1343 NF-kappa NF-kappa NNP 1344 1349 B/Rel B/Rel NNP 1350 1352 is be VBZ 1353 1359 likely likely JJ 1360 1362 to to TO 1363 1367 play play VB 1368 1370 an an DT 1371 1380 important important JJ 1381 1385 role role NN 1386 1388 in in IN 1389 1402 atherogenesis atherogenesis NN 1402 1403 . . .